Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Patients and data tracking

- PMLiVE

Roche to launch new innovation centre at Harvard’s Enterprise Research Campus

The first phase of construction on the ERC is expected to be complete in 2026

- PMLiVE

Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

Regulatory submissions are expected to be complete in the first half of this year

- PMLiVE

2025 PM Society Awards – winners announced

21GRAMS and Havas Lynx win big; AstraZeneca and UCB top client leader board

- PMLiVE

FREE WEBINAR – Not Just a Number: Making Sure Every Voice Shapes the Future of Medicine – Origins & ISPEP

What Does Patient-focused Healthcare Really Mean? Healthcare is built around patients, but too often, their voices are an afterthought. Truly patient-focused medicine isn’t just about treatment - it’s about understanding...

Origins – The Patient Focused Specialists

- PMLiVE

Prime minister unveils UK government’s plans to abolish NHS England

The move aims to cut waiting times and free up money for front-line services

- PMLiVE

AstraZeneca/Ionis’ Wainzua granted EC approval to treat rare disease ATTRv-PN

ATTRv with polyneuropathy affects up to 40,000 people worldwide

- PMLiVE

DSRU appoints Linda Härmark as director

Härmark is currently deputy director at the Netherlands Pharmacovigilance Centre Lareb

- PMLiVE

NEW WEBINAR! From Clicks to Outcomes: Measuring the Impact of Your Medical Education Platform

Struggling to quantify the value of your medical education platform and prove its ROI? Join our upcoming Pharma-exclusive webinar to learn real-work strategies and tips for developing a Med Ed...

Impetus Digital

- PMLiVE

World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

Approximately 10% of the UK population is affected by chronic kidney disease

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

The trial will evaluate the candidate in patients with antibody-mediated rejection

- PMLiVE

NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

Around 1,000 patients could benefit from the relugolix combination therapy every year

- PMLiVE

Roche and Zealand partner on mid-stage obesity candidate in deal worth $5.3bn

The companies will develop petrelintide as both a standalone therapy and in combination with Roche’s CT-388

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links